Entity

Time filter

Source Type

PITTSBURGH, PA, United States

Patent
Cognition Therapeutics, Inc. | Date: 2012-08-27

This invention relates to the use sigma-2 receptor antagonists, and of pharmaceutical compositions comprising such compounds, in methods for inhibiting Abeta-associated synapse loss or synaptic dysfunction in neuronal cells, modulating an Abeta-associated membrane trafficking change in neuronal cells, and treating cognitive decline associated with Abeta pathology and more broadly treating with such compounds and compositions neurodegenerative diseases and disorders associated with Abeta pathology. This invention also relates to methods for screening compounds for activity in inhibiting cognitive decline on the basis of their ability to bind to a sigma-2 receptor.


Patent
Cognition Therapeutics, Inc. | Date: 2012-08-27

This invention relates to novel diarylamino compounds that bind to the sigma-2 receptor, to pharmaceutical compositions comprising such compounds, and to methods for inhibiting or restoring synapse loss in neuronal cells, modulating a membrane trafficking change in neuronal cells, and treating cognitive decline and neurodegenerative diseases and disorders therewith.


Patent
Cognition Therapeutics, Inc. | Date: 2012-02-01

Compounds that are central nervous system drug candidates for the treatment of cognitive decline and, more particularly, Alzheimers disease are provided. Methods for treatment, inhibition, and/or abatement of cognitive decline and/or Alzheimers disease with a compound or pharmaceutically acceptable salt of the invention are also provided. Also provided are methods of preparing the compounds/compositions of the invention.


Patent
Cognition Therapeutics, Inc. | Date: 2010-04-06

Compounds that are central nervous system drug candidates for the treatment of cognitive decline and, more particularly, Alzheimers disease are provided. Methods of treating, inhibiting, and/or abatement of cognitive decline and/or Alzheimers disease with a compound or pharmaceutically acceptable salt of the invention are also provided. Also provided are methods of preparing the compounds/compositions of the invention.


Patent
Cognition Therapeutics, Inc. | Date: 2014-06-02

Compounds that are central nervous system drug candidates for the treatment of cognitive decline and, more particularly, Alzheimers disease are provided. Methods of treating, inhibiting, and/or abatement of cognitive decline and/or Alzheimers disease with a compound or pharmaceutically acceptable salt of the invention are also provided. Also provided are methods of preparing the compounds/compositions of the invention.

Discover hidden collaborations